Business wire
Case study demonstrates how personalized email components powered by AI can improve patient experience and boost medication adherence
Top Cardiovascular Medication Brand Sees 12.2% Increase in Therapy Adherence Rate with AllazoHealth’s AI-Enabled Dynamic Modular Emails
Media Contact:
Hilary McCarthy
774.364.1440
hilary@clearpointagency.com
AllazoHealth, the pioneer in driving therapy initiation, adherence, and health outcomes with artificial intelligence (AI)-powered personalization, today released a case study on a multinational pharmaceutical company’s use of AI-enabled dynamic modular emails to further personalize the patient experience, enhance email effectiveness, and increase medication adherence by 12.2%.
AllazoHealth used AI to predict the most effective email content for each patient prescribed the pharma company’s branded cardiovascular medication. Multiple versions of email content components, or modules, were created by the pharma company, including different subject lines, preview text, text blocks, images, and calls-to-action. When the modules were combined using AI that tailors based on each patient’s individual behaviors and preferences, it created a cohesive, dynamic email for each patient enabling the pharma company to quickly create personalized and impactful emails at scale.
The results of the case study showed that patients who received the AI-enabled dynamic emails achieved an 87.8% medication adherence rate versus 78.3% for patients who received only regular static emails.
Adherence to prescribed cardiovascular medications is associated with reductions in health care use such as emergency room visits and inpatient admissions, as well as lower overall medical costs. Additionally, these patients are more likely to see improvements in work productivity, and experience fewer sick days and less short- and long-term disability.
AllazoHealth CEO William Grambley said, “With regular static emails, there are fewer opportunities for personalization. You can personalize the subject line and choose delivery time and frequency of emails. But dynamic modular emails enabled with AI give pharmaceutical companies a variety of powerful ways to truly individualize the content. This case study shows how leveraging data, AI, and personalization can proactively drive measurable health outcomes. As we implement the AI solution and it learns from the dynamic modular content over time, we expect to see better performance and medication adherence consistently improve.”
As a result of this successful program, the pharma company has expanded its use of AllazoHealth’s AI-enabled dynamic modular emails to other patient email programs for different indications for the same drug.
“We’re seeing a shift in biopharmaceutical companies investing in patient experience initiatives designed to help them start and stay on therapy and improve overall health outcomes. AI-enabled dynamic modular content plays a vital role in those initiatives,” said Grambley.
About AllazoHealth
AllazoHealth is the pioneer driving therapy initiation, adherence, and health outcomes with AI-powered personalization. The technology optimizes patient programs by personalizing their experience. It has proven results across therapeutic areas from mass market to specialty and rare disease therapies. Using identified patient data and predictive AI, AllazoHealth creates the optimal engagement for each patient by personalizing every communication. AllazoHealth targets the right patients with the right message at the right time via the right channels - at scale - maximizing the impact and efficiency of pharmaceutical patient marketing and patient support programs. Built within Microsoft Azure, the platform is HIPAA compliant and HITRUST certified. AllazoHealth is named in PM360's Innovation Issue and is the winner of the FiercePharma Innovation Award. Learn more at https://allazohealth.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250127216905/en/
Add Comment